Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    A new revision entry (v3.5.4) was added to the page, replacing the previous revision (v3.5.3) in the study record’s history.
    Difference
    0.0%
    Check dated 2026-05-15T11:30:56.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    No Change Detected
  5. Check
    32 days ago
    Change Detected
    Summary
    ClinicalTrials.gov’s study page footer was updated to reflect a new site revision version (v3.5.3 instead of v3.5.2), with no visible change to the trial’s study details.
    Difference
    0.0%
    Check dated 2026-04-24T06:27:53.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Page revision tag updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-17T02:44:06.000Z thumbnail image
  7. Check
    68 days ago
    Change Detected
    Summary
    Revision updated from v3.4.3 to v3.5.0.
    Difference
    0.0%
    Check dated 2026-03-19T05:10:52.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    Revision: v3.4.3 is now displayed, replacing the previous Revision: v3.4.2.
    Difference
    0.0%
    Check dated 2026-03-12T00:00:45.000Z thumbnail image
  9. Check
    104 days ago
    Change Detected
    Summary
    A new site revision tag 'Revision: v3.4.2' was added, and the previous banner about government funding and the older revision 'v3.4.1' were removed.
    Difference
    0.4%
    Check dated 2026-02-11T14:19:39.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.